IND-Enabling Preclinical Studies

An Investigational New Drug application requires a coherent body of preclinical evidence establishing that a candidate has plausible activity, a characterized exposure profile, and an acceptable safety margin at the doses proposed for first administration to humans. Altogen Labs supports integrated preclinical programs that generate efficacy, pharmacology, safety, and mechanistic data to inform that development path.

The scope of an IND-enabling package is program specific and should be defined from the therapeutic modality, indication, route, dose, expected clinical use, and applicable regulatory strategy. A small molecule oncology candidate, a nucleic acid therapeutic, and a cell therapy product require substantially different packages, and a generic checklist applied across all three will over-specify some studies and omit others that matter.

To discuss what a specific program requires, request a quote.

What an integrated program combines

A program may combine in vivo efficacy studies, dose range finding, pharmacokinetics and pharmacodynamics, ADME and DMPK characterization, safety toxicology, clinical pathology, necropsy, histopathology, immunohistochemistry, tissue collection, biodistribution and imaging, and molecular endpoints. Studies may be exploratory or conducted under GLP standards where formally designated and appropriate.

Sequencing matters more than completeness

The most common source of wasted effort in IND-enabling work is not an omitted study but studies run in the wrong order. A GLP toxicology study conducted before the dose range has been established in a non-GLP setting will frequently select dose levels that produce either no findings or unmanageable toxicity, and the study must be repeated at full cost.

An efficient program establishes tolerability and exposure first, uses those data to select dose levels, and only then commits to the definitive studies. Efficacy and mechanism work proceeds in parallel rather than sequentially, since it informs indication selection and clinical dose rationale rather than gating the safety package. Altogen Labs will say where a proposed sequence is likely to require repetition rather than simply executing the studies as ordered.

Oncology and advanced modality programs

Oncology programs link validated tumor models with exposure and safety assessment, so the dose proposed for clinical use has both an efficacy and a tolerability basis in the same species where feasible.

Immuno-oncology, cellular therapy, RNA-based, and other advanced modality programs incorporate protocol-defined immune monitoring and tissue endpoints where scientifically appropriate. These modalities raise questions conventional small molecule packages do not: cytokine release for T-cell engaging agents, persistence and trafficking for cell therapies, and biodistribution of the delivery vehicle separate from the payload for nucleic acid therapeutics. Those endpoints are designed into the relevant studies rather than added afterward.

Applied examples

Dose rationale. Tolerability is established in a dose range finding study, exposure is characterized at the tolerated doses, and efficacy is demonstrated within that exposure range, producing a dose rationale in which the proposed clinical starting dose rests on three linked datasets rather than on an efficacy result alone.

Cell therapy package. A CAR-T candidate is evaluated for antitumor activity in a disseminated model, for persistence across the study duration, and for cytokine release in a humanized system, assembling the mechanism and safety-relevant data that a conventional immunodeficient efficacy study alone would not provide.

Nucleic acid program. A formulated oligonucleotide is assessed for tissue distribution, target knockdown in the intended organ, and off-target organ accumulation in the same study, so that exposure, activity, and the basis for organ-specific safety monitoring are established together.

Study planning, reporting, and scope limits

Protocols are written against pre-specified objectives with endpoints, acceptance criteria, and analysis plans defined before initiation, and data are reported in a form suitable for inclusion in a regulatory submission. Altogen Labs describes an integrated support framework rather than claiming that every possible IND study type is performed in house, and will state plainly which elements of a package fall outside its scope so a program can plan for them rather than discover the gap late. All in vivo procedures are conducted under active IACUC protocols. GLP standards are applied where a study is formally designated as GLP.

Send modality, indication, intended route, and regulatory timeline, or request a quote.